176 related articles for article (PubMed ID: 16773030)
1. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
Flys TS; Chen S; Jones DC; Hoover DR; Church JD; Fiscus SA; Mwatha A; Guay LA; Mmiro F; Musoke P; Kumwenda N; Taha TE; Jackson JB; Eshleman SH
J Acquir Immune Defic Syndr; 2006 Aug; 42(5):610-3. PubMed ID: 16773030
[TBL] [Abstract][Full Text] [Related]
2. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
Flys TS; Donnell D; Mwatha A; Nakabiito C; Musoke P; Mmiro F; Jackson JB; Guay LA; Eshleman SH
J Infect Dis; 2007 Mar; 195(5):711-5. PubMed ID: 17262714
[TBL] [Abstract][Full Text] [Related]
3. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
Church JD; Hudelson SE; Guay LA; Chen S; Hoover DR; Parkin N; Fiscus SA; Mmiro F; Musoke P; Kumwenda N; Jackson JB; Taha TE; Eshleman SH
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):764-8. PubMed ID: 17604538
[TBL] [Abstract][Full Text] [Related]
4. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
Flys T; Nissley DV; Claassen CW; Jones D; Shi C; Guay LA; Musoke P; Mmiro F; Strathern JN; Jackson JB; Eshleman JR; Eshleman SH
J Infect Dis; 2005 Jul; 192(1):24-9. PubMed ID: 15942890
[TBL] [Abstract][Full Text] [Related]
5. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
[TBL] [Abstract][Full Text] [Related]
6. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
Jackson JB; Becker-Pergola G; Guay LA; Musoke P; Mracna M; Fowler MG; Mofenson LM; Mirochnick M; Mmiro F; Eshleman SH
AIDS; 2000 Jul; 14(11):F111-5. PubMed ID: 10983633
[TBL] [Abstract][Full Text] [Related]
7. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
Flys TS; Mwatha A; Guay LA; Nakabiito C; Donnell D; Musoke P; Mmiro F; Jackson JB; Eshleman SH
AIDS; 2007 Oct; 21(15):2077-82. PubMed ID: 17885298
[TBL] [Abstract][Full Text] [Related]
8. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
Jones D; Parkin N; Hudelson SE; Guay LA; Musoke P; Mmiro F; Jackson JB; Eshleman SH
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
Eshleman SH; Hoover DR; Chen S; Hudelson SE; Guay LA; Mwatha A; Fiscus SA; Mmiro F; Musoke P; Jackson JB; Kumwenda N; Taha T
J Infect Dis; 2005 Jul; 192(1):30-6. PubMed ID: 15942891
[TBL] [Abstract][Full Text] [Related]
10. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
[TBL] [Abstract][Full Text] [Related]
11. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
[TBL] [Abstract][Full Text] [Related]
12. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
Eshleman SH; Guay LA; Wang J; Mwatha A; Brown ER; Musoke P; Mmiro F; Jackson JB
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):24-9. PubMed ID: 16123677
[TBL] [Abstract][Full Text] [Related]
14. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
Loubser S; Balfe P; Sherman G; Hammer S; Kuhn L; Morris L
AIDS; 2006 Apr; 20(7):995-1002. PubMed ID: 16603851
[TBL] [Abstract][Full Text] [Related]
15. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
Eshleman SH; Becker-Pergola G; Deseyve M; Guay LA; Mracna M; Fleming T; Cunningham S; Musoke P; Mmiro F; Jackson JB
J Infect Dis; 2001 Oct; 184(7):914-7. PubMed ID: 11509999
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
Kuhn L; Sinkala M; Kankasa MP; Kasonde P; Thea DM; Aldrovandi GM
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):260-2. PubMed ID: 16760802
[No Abstract] [Full Text] [Related]
17. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S; Boltz V; Martinson N; Maldarelli F; Gray G; McIntyre J; Mellors J; Morris L; Coffin J
Proc Natl Acad Sci U S A; 2006 May; 103(18):7094-9. PubMed ID: 16641095
[TBL] [Abstract][Full Text] [Related]
18. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
[TBL] [Abstract][Full Text] [Related]
19. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
Johnson JA; Li JF; Morris L; Martinson N; Gray G; McIntyre J; Heneine W
J Infect Dis; 2005 Jul; 192(1):16-23. PubMed ID: 15942889
[TBL] [Abstract][Full Text] [Related]
20. Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Micek MA; Blanco AJ; Carlsson J; Beck IA; Dross S; Matunha L; Seidel K; Montoya P; Gantt S; Matediana E; Jamisse L; Gloyd S; Frenkel LM
J Infect Dis; 2012 Jun; 205(12):1811-5. PubMed ID: 22492850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
